FCH
NTLA icon

Freestone Capital Holdings’s Intellia Therapeutics NTLA Stock Holding History

Freestone Capital Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200
Closed -$10.9K – 867
2020
Q4 		$10.9K Hold
200
– – ﹤0.01% 839
2020
Q3 		$3.98K Buy
+200
New +$4.17K ﹤0.01% 923

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Freestone Capital Holdings's NTLA Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 200 shares — an estimated $10.9K sold.

Freestone Capital Holdings first reported a position in NTLA in Q3 2020 and held it in 2 quarters. The position peaked at $10.9K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 200 Intellia Therapeutics shares in Q1 2021, an estimated $10.9K.
  • Freestone Capital Holdings first reported a position in Intellia Therapeutics in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's Intellia Therapeutics position peaked at $10.9K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.